ATXN2 and neuroblastoma: Treating human neurons (induced pluripotent stem cell [iPSC]-derived or neuroblastoma SH-SY5Y cells) for 24 h with etidronate, alendronate, or thonzonium resulted in dose-dependent decreases in ataxin-2 protein levels (Figures 4A–4C, S5A, S5B, S6A, and S6B).